ImmunityBio’s (IBRX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a research report released on Tuesday morning,Benzinga reports. The firm currently has a $24.00 price objective on the stock.

IBRX has been the subject of several other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImmunityBio in a research report on Monday, December 29th. Jefferies Financial Group increased their price target on shares of ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a report on Friday, December 12th. Finally, Piper Sandler raised their price target on shares of ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a research report on Tuesday. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, ImmunityBio has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

ImmunityBio Stock Up 6.1%

Shares of IBRX opened at $7.34 on Tuesday. The stock has a market cap of $7.23 billion, a P/E ratio of -17.90 and a beta of 0.03. The business’s 50 day moving average price is $2.65 and its 200-day moving average price is $2.55. ImmunityBio has a 52 week low of $1.83 and a 52 week high of $8.28.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. The company had revenue of $32.06 million for the quarter, compared to the consensus estimate of $31.88 million. On average, equities analysts anticipate that ImmunityBio will post -0.92 EPS for the current year.

Insider Activity at ImmunityBio

In other ImmunityBio news, Director Christobel Selecky sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $5.00, for a total value of $250,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Barry J. Simon sold 151,967 shares of the firm’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $7.20, for a total transaction of $1,094,162.40. Following the sale, the director owned 3,091,604 shares in the company, valued at $22,259,548.80. The trade was a 4.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 226,967 shares of company stock worth $1,531,912 in the last ninety days. Insiders own 69.48% of the company’s stock.

Institutional Investors Weigh In On ImmunityBio

Institutional investors and hedge funds have recently bought and sold shares of the business. Slow Capital Inc. purchased a new stake in shares of ImmunityBio during the third quarter worth about $25,000. Truist Financial Corp purchased a new position in ImmunityBio in the 3rd quarter worth approximately $27,000. Swiss Life Asset Management Ltd bought a new position in ImmunityBio in the 3rd quarter worth approximately $27,000. Diversify Advisory Services LLC purchased a new stake in ImmunityBio during the 2nd quarter valued at approximately $27,000. Finally, Summit X LLC bought a new stake in shares of ImmunityBio during the second quarter valued at approximately $28,000. 8.58% of the stock is owned by institutional investors.

More ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: FDA discussions gave a clearer path to resubmit an sBLA for ANKTIVA in papillary non‑muscle invasive bladder cancer; ImmunityBio plans additional analyses and a filing soon. Read More.
• Positive Sentiment: HC Wainwright reaffirmed bullish coverage and raised long‑term outlook (FY2030 EPS estimate to $0.68), signaling rising analyst optimism about the company’s commercial prospects. Read More.
• Positive Sentiment: Recent company announcements about clinical results and an expansion plan have been cited in coverage characterizing the move as a strong rally, which has attracted momentum buyers. Read More.
• Neutral Sentiment: Short‑seller pain and a multi‑day rally are amplifying volume and volatility; technical short covering can sustain gains short‑term but doesn’t guarantee fundamentals. Read More.
• Neutral Sentiment: Multiple outlets note the stock’s extended run (reported as a 12‑day advance in some coverage), suggesting momentum trading is a significant component of the move. Read More.
• Negative Sentiment: Company insiders have sold shares recently (director Christobel Selecky and director Barry J. Simon among reported transactions), which investors often view as a caution signal on near‑term risk. Read More.
• Negative Sentiment: High‑profile commentators (e.g., Jim Cramer) have advised trimming positions and taking profits, highlighting opinion that the recent run may be speculative. Read More.
• Negative Sentiment: Some analysts warn momentum risks and that regulatory requests could require more data or time than investors expect — a potential downside if the sBLA resubmission is delayed or expanded. Read More.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.